Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 15/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 13/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 13/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26807463 | 0.92 | ACVR1 (0.40) | NOD2RIPK2ACVR1TGFBR1 | |
| SCHEMBL29566726 | 0.89 | RIPK2 (0.39) | NOD2RIPK2ACVR1FLT3KMT2A | |
| SCHEMBL26807316 | 0.89 | RIPK2 (0.39) | NOD2RIPK2ACVR1FLT3KMT2A | |
| SCHEMBL26807466 | 0.88 | FLT3 (0.38) | NOD2RIPK2ACVR1FLT3LCK | |
| SCHEMBL26807471 | 0.85 | ACVR1 (0.40) | NOD2RIPK2ACVR1FLT3TGFBR1 | |
| SCHEMBL24310583 | 0.85 | RIPK2 (0.38) | NOD2RIPK2ACVR1FLT3LCK | |
| SCHEMBL24309512 | 0.85 | FLT3 (0.36) | NOD2RIPK2ACVR1FLT3 | |
| SCHEMBL24309665 | 0.85 | GUSB (0.39) | NOD2RIPK2ACVR1FLT3 | |
| SCHEMBL29566865 | 0.85 | GUSB (0.39) | NOD2RIPK2ACVR1FLT3 | |
| SCHEMBL26807474 | 0.85 | RIPK2 (0.35) | NOD2RIPK2ACVR1FLT3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NOD2 724/4885RIPK2 3698/4885ACVR1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.